Business
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer
OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Tria...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\nOncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nEDMONTON, March 24, 2020\n\n\n\nEDMONTON, March 24, 2020 /CNW/ - OncoQuest Inc. (\"OncoQuest\" or the \"Company\"), a privately held, cancer immunotherapy company today announced the publication of two reports relating to the recently completed Phase 2 trial conducted in the US and Italy utilizing oregovomab, the Company's lead investigational drug in frontline ovarian cancer. \nThe first report which appears in the journal Gynecologic Oncology is titled Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study, reported the clinical results in the completed 97-patient randomized controlled multi-site study in which 47 patients were randomized to receive chemoimmunotherapy with standard carboplatin and paclitaxel chemotherapy combined with oregovomab or standard chemotherapy (standard carboplatin and paclitaxel).\nThe study was conducted with a median of 42 months follow up and shows highly statistically significant outcomes for both progression-free and overall survival favoring the chemoimmunotherapy arm. The risk of progression and of death was reduced by more than 50% in the chemoimmunotherapy arm. Safety data shows that the addition of orgeovomab did not add incremental toxicity to chemotherapy.\nThe second report published in Cancer Immunology, Immunotherapy is titled Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer.  The report examined translational laboratory outcomes from a subset of the Italian cohort of patients in the above described study from the laboratory of Professor Scambia at Catholic University Hospital in Rome. The report confirms that chemoimmunotherapy increased the pr...